CTNM Stock Analysis: Buy, Sell, or Hold?
CTNM - Contineum Therapeutics, Inc. Class A Common Stock
$17.19
1.17 (7.30%)
▲
5d:
+21.14%
30d:
+19.62%
90d:
+19.62%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When CTNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CTNM is 11.8% above its trading range ($15.38). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CTNM is 11.8% above its trading range ($15.38). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CTNM is currently trading at $17.19, which is considered fair relative to its 30-day fair value range of $14.10 to $15.38.
Technical Outlook: Technically, CTNM is in a strong uptrend. The price is approaching resistance at $17.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: CTNM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.43 (+36.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTNM is in a strong uptrend. The price is approaching resistance at $17.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: CTNM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.43 (+36.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$14.10 -
$15.38
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.3%)
- BULLISH: Trading 36.3% below Wall St target ($23.43)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.10 -
$15.38
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$14.10
Resistance Level
$17.35
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.57
Wall Street Target
$23.43
(+36.3%)
Share & Embed Analysis
Last updated: August 23, 2026 1:00 AM ET
Data refreshes hourly during market hours. Next update: 2:00 AM
Data refreshes hourly during market hours. Next update: 2:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTNM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 50 HOLD |
